QTTB backs Phase II bempikibart results for Phase III move
Positive Phase II data for bempikibart in alopecia areata, with JAK-like efficacy and a strong safety profile, support plans to advance to Phase III and explore additional indications.
Positive phase II data for bempikibart in alopecia areata showed JAK-like efficacy and a strong safety profile, with plans to advance to phase III and to explore additional indications. Upcoming milestones include new data releases, regulatory guidance and pipeline expansion decisions. Based on Q32 Bio…